We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

60 hedge funds and large institutions have $14M invested in Citius Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

541% more call options, than puts

Call options by funds: $468K | Put options by funds: $73K

0.25% less ownership

Funds ownership: 0.66% → 0.42% (-0.25%)

21% less funds holding

Funds holding: 76 → 60 (-16)

39% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 18

48% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 29

68% less capital invested

Capital invested by funds: $43.2M → $14M (-$29.3M)

Holders
60
Holders Change
-16
Holders Change %
-21.05%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
11
Reduced
18
Closed
29
Calls
$468K
Puts
$73K
Net Calls
+$395K
Net Calls Change
-$518K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.91M
2
E
Ergoteles
New York
+$496K
3
Renaissance Technologies
Renaissance Technologies
New York
+$374K
4
Morgan Stanley
Morgan Stanley
New York
+$177K
5
Citadel Advisors
Citadel Advisors
Florida
+$136K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.29M
2
State Street
State Street
Massachusetts
-$1.78M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.06M
4
Allspring Global Investments
Allspring Global Investments
North Carolina
-$928K
5
Northern Trust
Northern Trust
Illinois
-$904K
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
26
Rafferty Asset Management
New York
$46K -$2.36K -86 -4%
MIM
27
Miller Investment Management
Pennsylvania
$46K – – –
Simplex Trading
28
Simplex Trading
Illinois
$38K +$29.3K +1,068 +171%
PAG
29
Private Advisor Group
New Jersey
$37K – – –
BFM
30
Boothbay Fund Management
New York
$36K +$43.1K +1,571 New
Osaic Holdings
31
Osaic Holdings
Arizona
$32K – – –
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$25K – – –
AQR Capital Management
33
AQR Capital Management
Connecticut
$23K +$27.7K +1,011 New
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$21K +$1.65K +60 +7%
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$20.4K +$9.07K +331 +60%
YIH
36
Y-Intercept (HK)
Hong Kong
$16K +$19K +694 New
CAG
37
Csenge Advisory Group
Florida
$14K +$16.5K +600 New
US Bancorp
38
US Bancorp
Minnesota
$11K – – –
CSS
39
Cubist Systematic Strategies
Connecticut
$11K +$12.6K +461 New
WJWM
40
Williams Jones Wealth Management
New York
$9K – – –
Barclays
41
Barclays
United Kingdom
$6K -$14.8K -540 -67%
Wells Fargo
42
Wells Fargo
California
$5K -$27.2K -993 -84%
APA
43
American Portfolios Advisors
New York
$3.68K – – –
GIA
44
GHP Investment Advisors
Colorado
$3K – – –
CAPTRUST Financial Advisors
45
CAPTRUST Financial Advisors
North Carolina
$2K -$7.79K -284 -74%
SSC
46
Syverson Strege & Co
Iowa
$2K – – –
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$1K -$56K -2,041 -98%
UBS Group
48
UBS Group
Switzerland
$1K -$25.3K -924 -95%
Citigroup
49
Citigroup
New York
$1K -$10.7K -389 -90%
IA
50
IFP Advisors
Florida
$1K – – –
1
2
3 4

CTXR Hedge Fund Activity: Q2 2022 in Review

60 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2022, worth a combined $14M — down 68% from $43.2M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of CTXR and 15 opened new positions — a net loss of 14 holders — while 18 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.91M. The largest seller was BlackRock, cutting an estimated $6.29M.

  • 60 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2022, down from 76 in Q1 2022.
  • Funds reported $14M of Citius Pharmaceuticals stock for Q2 2022, down 68% quarter-over-quarter.
  • 15 funds opened new Citius Pharmaceuticals positions in Q2 2022 and 29 closed out, a net change of -14 holders.
  • The largest Citius Pharmaceuticals buyer in Q2 2022 was Millennium Management, an estimated $1.91M added.
  • The largest Citius Pharmaceuticals seller in Q2 2022 was BlackRock, an estimated $6.29M sold.

Based on aggregated 13F filings for Q2 2022.